Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

The FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.

GSK shares sink after FDA panel rejects Blenrep cancer drug, raising doubts over turnaround strategy. GSK (LSE: GSK) investors took a sharp knock on Friday after its much-hyped blood cancer drug, ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first treatment didn’t work or who had severe side effects.

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

Job growth is forecast to remain steady in April, though slower than in March. Early signs of impact from federal workforce cuts, trade policy shifts, and immigration changes may emerge, with ...

Blenrep had previously been approved in the U.S., European Union, U.K., and other countries, but GSK pulled it from the market in 2022 after the drug failed in a study meant to confirm its benefit ...

Blenrep, when combined with other therapies, has since succeeded in two key studies in previously treated blood cancer patients. Under its original approval, it was used on its own.